Adagrasib provides antitumor activity against metastatic KRAS G12C-mutated colorectal cancer as monotherapy and in combination with cetuximab.

1. The general tumor response to monotherapy with adagrasib was 23% and 46% together with cetuximab. 2. The median progression-free survival was 5.6 months on adagrasib monotherapy and 6.9 months on mixture remedy with cetuximab. Proof classification degree: 2 (good) Research rundown: An oncogene homolog of the Kirsten rat sarcoma virus (Brochure) It’s answerable for … Read more